Gx™ Inherited Cancer Gene Testing (Gx™ InhCa)
Analyzes 39 genes linked to breast, ovarian, colorectal, pancreatic, and other major types of cancers
Early cancer screen contributes to greatly increased life expectancy in the US, according to a recent report in JAMA Internal Medicine. Approximately 0.3% of the population are carriers of a genetic mutation that has a large effect on cancer risk, accounting for about 5–10% of all cancers. Gx™ InhCa analysis 39 genes associated with major types of cancers, offering an effective tool for cancer risk screen and diagnosis. 
The testing Provides:
- Diagnosis of clinical condition
- Assess cancer susceptibility
- Identification of at-risk family members
- Guidance for disease prognosis
- Implications for therapeutic drugs
Candidates for Gx™ InhCa Testing
- Patient with a family history of cancers
- Patients who are at risk for other cancers
- Patients with pre-cancer conditions
Flexible Options to Select Testing for a Subset of 39 Gx™ InhCa Genes:
- Gx™ BrCa1/2 – BRCA1 and BRCA2 genes, sequencing and Del/Dup
- Gx™ BrOvCa – 15 Genes linked to breast and ovarian cancers
- Gx™ CRCa – 12 Genes linked to colorectal cancers
- Gx™ LynS – 5 Genes linked to Lynch Syndrome
39 Genes Sampled
Gx™ BrCa1/2:
Gx™ BrOvCa:
ATM, BRCA1, BRCA2, BRIP1, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, RAD51C, RET, STK11, TP53, VHL
Gx™ CRCa:
APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, MUTYH, PTEN, PMS2, SMAD4, STK11